Microwave Ablation in Chinese Patients With Lung Tumors (NCT04889989) | Clinical Trial Compass
TerminatedNot Applicable
Microwave Ablation in Chinese Patients With Lung Tumors
Stopped: Change in company strategy.
China13 participantsStarted 2021-12-27
Plain-language summary
Adult patients with non-small cell lung cancer (NSCLC) or oligometastatic lung tumors will all receive microwave ablation (MWA) performed percutaneously by doctors who are experienced in lung tumor ablation. 120 patients will participate across 8 clinical study sites all in China.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Signed the informed consent form and willing to fulfill the study-related assessments and procedure schedule.
✓. Lung tumor patients ≥ 18 years of age who are ineligible for/decline surgery and who plan to receive microwave ablation therapy.
✓. ECOG performance status score of 0-2.
✓. Patients with stages IA1-IA2 NSCLC with documented results from a biopsy or patients with clinically diagnosed oligometastatic lung tumor.
✓. Tumor(s) to be ablated in a single surgery should be a maximum of one NSCLC tumor or a maximum of three ipsilateral oligometastatic lung tumors.
✓. Tumor(s) to be ablated in a single surgery should be ≤ 2cm, locate in the outer two-thirds of a lung, not closer than 1 cm from the hilum of lung, great vessels, principal bronchus, trachea or esophagus, and not contiguous with the pleura.
Exclusion criteria
✕. Pregnant or breast-feeding.
✕. Patients with implantable pacemakers or other electronic implants.
✕. Oligometastatic tumors patients whose primary lesion cannot be controlled or have widely metastases, in the opinion of the investigator and/or treating oncologist.
✕. Any planned concurrent procedure at the time of ablation.
✕. Planned treatment for other tumors in the same side lung during the study period.